Serum microRNA-122 and AFP Levels for Predicting Early Treatment Failure in Liver Cancer

64 consecutive patients with unresectable hepatocellular carcinoma (HCC) were retrospectively analyzed between October 2020 and January 2026. The study, authored by figshare admin karger and published on figshare, investigates baseline serum microRNA-122 (miR-122) and AFP levels as predictors of early progressive disease within 6 weeks of atezolizumab plus bevacizumab therapy.

Use Cases

• Predict early progressive disease in HCC patients based on baseline serum miR-122 levels.
• Identify high-risk patient subgroups for treatment failure using AFP and miR-122 thresholds.
• Validate biomarker performance for immunotherapy regimens in oncology clinical trials.
• Correlate clinical and laboratory characteristics with radiological progression outcomes.

Strengths

• Data covers 64 consecutive patients with HCC.
• Analysis includes multivariate logistic regression identifying independent predictors.
• Results were validated in a subset of cases without prior targeted therapy.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal bias inherent to the single-center retrospective study design.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patient records and serum samples.

Time Range

October 2020 to January 2026

Freshness

Last updated 2026-04-13 05:55:09; freshness should be verified.

Geography

null